Related Experiment Video
Updated: Aug 22, 2025
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Clinical evidence supporting cefiderol for serious Acinetobacter baumannii infections
Matteo Bassetti1,2, Antonio Vena1,2, Nadia Castaldo3
1Infectious Diseases Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences.
Purpose Of Review:
Nosocomial infections caused by Acinetobacter baumannii currently represent a serious challenge for clinicians because treatment options are limited and frequently associated with significant toxicity. Cefiderocol is a first-in-class siderophore cephalosporin that has a proven efficacy for the treatment of multidrug-resistant Gram-negative infections, including carbapenem-resistant A. baumannii. The aim of this review is to evaluate the current evidence for the role of cefiderocol in the management of A. baumannii infections.
Recent Findings:
In this review, we briefly summarize the available data on the efficacy (from randomized controlled trials) and on effectiveness and cure rates (from observational studies), pertaining to the use of cefiderocol for treatment of serious A. baumannii infections.
Summary:
Cefiderocol represents a promising and safe antibiotic option for treating patients with carbapenem-resistant A. baumannii infections. Due to conflicting mortality data from available experience, well-designed future randomized controlled trials and real-life studies are needed.
Insights
Cefiderocol shows promise for treating Acinetobacter baumannii infections, particularly multidrug-resistant strains. Further research is needed to confirm its effectiveness and address conflicting mortality data in clinical settings.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Nosocomial infections caused by Acinetobacter baumannii present a significant clinical challenge due to limited and toxic treatment options.
- Multidrug-resistant Gram-negative infections, including carbapenem-resistant A. baumannii, necessitate novel therapeutic strategies.
- Cefiderocol, a novel siderophore cephalosporin, offers a potential solution for these challenging infections.
Approach:
- This review synthesizes current evidence on cefiderocol's efficacy and effectiveness.
- Data from randomized controlled trials (RCTs) and observational studies are summarized.
- The focus is on the management of serious Acinetobacter baumannii infections.
Key Points:
- Cefiderocol demonstrates efficacy in treating carbapenem-resistant Acinetobacter baumannii infections.
- Evidence from RCTs and observational studies supports its use.
- Safety and cure rates are evaluated for serious A. baumannii infections.
Conclusions:
- Cefiderocol is a promising and safe antibiotic for carbapenem-resistant A. baumannii infections.
- Conflicting mortality data necessitate further investigation.
- Well-designed future RCTs and real-world studies are crucial to solidify its role.
More Related Videos
07:41Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization
Published on: August 4, 2023
07:59Rapid and Specific Detection of Acinetobacter baumannii Infections Using a Recombinase Polymerase Amplification/Cas12a-based System
Published on: April 25, 2025
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:28Antimicrobial Effectiveness